Why the Perceptive Discovery and Nucleus RadioPharma agreement matters for oncology drug development
Perceptive Discovery and Nucleus RadioPharma link imaging and manufacturing to address critical bottlenecks in radiopharmaceutical development.
Medical Devices & Diagnostics
Pharma & Biotech
Accro Bioscience’s $50m round signals growing interest in targeted IBD immunology
IBD needs safer oral options. Accro’s $50 million raise puts RIPK2 inhibition closer to a decisive clinical test.